How CAR T-Cell Therapy Impacts Relapsed/Refractory MM Treatment

Opinion
Video

Yi Lin, MD, PhD, provides insights on the impact of CAR T-cell therapy on the evolving multiple myeloma treatment landscape.

Video content above is prompted by the following questions:

  • What is the impact of CAR T-cell therapy on patient quality of life and how does it compare to other available treatments?
    • How do patients typically respond to CAR T-cell therapy in terms of their overall well-being and ability to perform daily activities?
    • Are there any long-term quality of life benefits or challenges associated with CAR T-cell therapy?
Recent Videos
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Prophylactic steroid or tocilizumab use may help in preventing CRS in patients undergoing treatment with bispecific antibodies for multiple myeloma.
Related Content